Cellebrite DI (NASDAQ:CLBT) PT Raised to $23.00

Cellebrite DI (NASDAQ:CLBT) had its price objective upped by TD Cowen from $20.00 to $23.00 in a research note published on Monday, Benzinga reports. They currently have a buy rating on the stock.

CLBT has been the topic of several other reports. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a buy rating in a research report on Friday, August 16th. JPMorgan Chase & Co. raised their price target on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an overweight rating in a research report on Wednesday, August 14th. Bank of America upped their price objective on Cellebrite DI from $13.00 to $17.00 and gave the company a buy rating in a research report on Friday, August 16th. Needham & Company LLC lifted their target price on Cellebrite DI from $14.00 to $17.00 and gave the stock a buy rating in a report on Friday, August 16th. Finally, Craig Hallum upped their price target on Cellebrite DI from $16.00 to $20.00 and gave the company a buy rating in a report on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of Buy and an average target price of $18.57.

Cellebrite DI Trading Up 3.5 %

CLBT stock opened at $17.22 on Monday. The firm has a 50 day moving average price of $15.43 and a 200-day moving average price of $12.79. Cellebrite DI has a 52-week low of $6.36 and a 52-week high of $17.82.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The business had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $91.94 million. During the same quarter in the previous year, the business earned $0.05 earnings per share. The firm’s quarterly revenue was up 24.8% compared to the same quarter last year. Research analysts predict that Cellebrite DI will post 0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Cellebrite DI by 59.6% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares during the period. Parallel Advisors LLC increased its holdings in Cellebrite DI by 75.0% during the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after buying an additional 1,500 shares during the last quarter. Quarry LP bought a new position in Cellebrite DI in the fourth quarter worth approximately $36,000. Public Employees Retirement Association of Colorado purchased a new position in shares of Cellebrite DI during the 2nd quarter worth $71,000. Finally, nVerses Capital LLC bought a new stake in shares of Cellebrite DI during the 2nd quarter valued at $103,000. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.